Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury
JCI Insight · 2026
DOI: 10.1172/jci.insight.200429 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Bryce C Murillo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Myocytes, Cardiac, Protein-Tyrosine Kinases, Cell Cycle. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NHLBI Division of Intramural Research.
Abstract (Originalsprache)
The adult mammalian heart has a limited ability to regenerate lost myocardium following myocardial infarction (MI), largely due to the poor proliferative capacity of cardiomyocytes (CMs). Dual-specificity tyrosine phosphorylation–regulated kinase 1A (DYRK1A) is a known regulator of cell quiescence, though the mechanisms underlying its function remain unclear. Previous studies have shown that pharmacological inhibition of DYRK1A using harmine induces CM cell cycle reentry after ischemia/reperfusion (I/R) MI. Here, we developed a computational network model of DYRK1A-mediated regulation of the cell cycle, which predicts how DYRK1A inhibition promotes CM reentry. To validate these predictions, we tested selective DYRK1A inhibitors and observed robust induction of cell cycle activity in neonatal rat cardiomyocytes (NRCMs). Integrating our network model with bulk RNA sequencing data from DYRK1A inhibitor–treated NRCMs, we identified E2F1 as a key transcriptional driver of cell cycle gene expression. Finally, we demonstrate that both pharmacological and post-developmental inhibition of DYRK1A enhances heart function and increases CM cycling following I/R MI. Our findings suggest that functional recovery induced by small-molecule inhibitors of DYRK1A is mediated by the induction of cycling CMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology.
- Department of Medicine.
- Department of Biomedical Engineering, and.
- Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA.
- Perha Pharmaceuticals, Roscoff, France.
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NHLBI Division of Intramural Research
- NIGMS
Zitieren
APA
Murillo, B. C., Young, A., Wintruba, K. L., Eichert, A. J., Siejda, K., Hoernig, D., Bradley, L. A., Harris, B. N., Zhao, C., Wu, M., Deau, E., Lindberg, M. F., Meijer, L., Saucerman, J. J., & Wolf, M. J. (2026). Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury. JCI Insight. https://doi.org/10.1172/jci.insight.200429
Vancouver
Murillo BC, Young A, Wintruba KL, Eichert AJ, Siejda K, Hoernig D, et al. Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury. JCI Insight. 2026. doi:10.1172/jci.insight.200429
BibTeX
@article{Murillo2026,
author = {Murillo, Bryce C and Young, Alexander and Wintruba, Kaitlyn L and Eichert, Alexander J and Siejda, Klara and Hoernig, Dennon and Bradley, Leigh A and Harris, Bryana N and Zhao, Catherine and Wu, Michelle and Deau, Emmanuel and Lindberg, Mattias F and Meijer, Laurent and Saucerman, Jeffrey J and Wolf, Matthew J},
title = {Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.200429}
}
EUVIMED